Malarone Pediátrico (Proguanil Hydrochloride, Atovaquone)

Atovaquone blocks the mitochondrial electron transport chain of the malaria parasite, halting energy production, while proguanil is converted to cycloguanil, which inhibits the parasite’s dihydrofolate reductase enzyme. Together they stop parasite replication and lead to parasite death.

The specific dose of Malarone Pediátrico is determined by the prescribing clinician based on the child’s age, weight, and the intended use (prophylaxis or treatment). Dosing instructions are provided on the prescription label and should be followed exactly.

Safety data for atovaquone/proguanil in pregnancy and lactation are limited. The medication should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by a qualified healthcare professional.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Malarone Pediátrico offers a fixed‑dose combination that provides both prophylactic and therapeutic activity, reducing the need for separate drugs. Compared with older agents such as chloroquine, it retains efficacy against many resistant Plasmodium strains, though cost and availability may differ from alternatives like doxycycline or mefloquine.

Store the tablets at ambient temperature below 25 °C, in the original blister pack, protected from moisture and direct sunlight. Do not refrigerate or freeze the product, and keep it out of reach of children.

Malarone Pediátrico is taken orally with water, usually with food to improve absorption. The tablet should be swallowed whole and not chewed or crushed unless specifically instructed by a healthcare professional.

Serious risks include severe skin reactions such as Stevens‑Johnson syndrome, hepatic dysfunction, significant neutropenia, and rare cases of anaphylaxis. Patients should seek immediate medical attention if they develop rash, jaundice, fever, or breathing difficulties.

Malarone Pediátrico should be avoided in children with known hypersensitivity to atovaquone, proguanil, or any component of the formulation, and in those with severe G6PD deficiency. Caution is also advised for patients with significant liver or kidney disease.